{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:59:33Z","timestamp":1789581573287,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Bavarian Cancer Research Center"},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Faculty LMU, \"F\u00f6FoLe\"","award":["1147"],"award-info":[{"award-number":["1147"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05507-9","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T10:01:31Z","timestamp":1697796091000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy"],"prefix":"10.1007","volume":"103","author":[{"given":"Michael","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Blumenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Quell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit L.","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ingenerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska J.","family":"Dekorsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"5507_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169","journal-title":"N Engl J Med"},{"key":"5507_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"5507_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545\u20132554. https:\/\/doi.org\/10.1056\/NEJMoa1708566","journal-title":"N Engl J Med"},{"key":"5507_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"5507_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"key":"5507_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"5507_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, Lopez JA, Chen J, Chung D, Harju-Baker S et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"5507_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"5507_CR9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5:2799\u20132806. https:\/\/doi.org\/10.1182\/bloodadvances.2021004575","journal-title":"Blood Adv"},{"key":"5507_CR10","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, Batlevi C, Brentjens RJ, Dahi PB, Devlin SM et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5:3397\u20133406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885","journal-title":"Blood Adv"},{"key":"5507_CR11","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ et al (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4:5414\u20135424. https:\/\/doi.org\/10.1182\/bloodadvances.2020003092","journal-title":"Blood Adv"},{"key":"5507_CR12","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV et al (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133:2212\u20132221. https:\/\/doi.org\/10.1182\/blood-2018-12-893396","journal-title":"Blood"},{"key":"5507_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"5507_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"key":"5507_CR15","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood-2022-167187","volume":"140","author":"R Bansal","year":"2022","unstructured":"Bansal R, Paludo J, Hathcock MA, Spychalla MT, Khurana A, Hampel PJ, Durani U, Alkhateeb HB, Dingli D, Hayman SR et al (2022) Outpatient practice pattern for recently approved CAR-T in patients with lymphoma and multiple myeloma. Blood 140:2399\u20132401. https:\/\/doi.org\/10.1182\/blood-2022-167187","journal-title":"Blood"},{"key":"5507_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","volume":"57","author":"A Borogovac","year":"2022","unstructured":"Borogovac A, Keruakous A, Bycko M, HolterChakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT et al (2022) Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant 57:1025\u20131027. https:\/\/doi.org\/10.1038\/s41409-022-01664-z","journal-title":"Bone Marrow Transplant"},{"key":"5507_CR17","doi-asserted-by":"publisher","first-page":"20210448","DOI":"10.1259\/bjr.20210448","volume":"94","author":"M Meignan","year":"2021","unstructured":"Meignan M, Cottereau AS, Specht L, Mikhaeel NG (2021) Total tumor burden in lymphoma - an evolving strong prognostic parameter. Br J Radiol 94:20210448. https:\/\/doi.org\/10.1259\/bjr.20210448","journal-title":"Br J Radiol"},{"key":"5507_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.critrevonc.2013.11.002","volume":"90","author":"PG Gobbi","year":"2014","unstructured":"Gobbi PG (2014) Tumor burden in Hodgkin\u2019s lymphoma: much more than the best prognostic factor. Crit Rev Oncol Hematol 90:17\u201323. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.11.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"5507_CR19","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.ejca.2011.06.012","volume":"47","author":"C Gomez-Roca","year":"2011","unstructured":"Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferte C, Massard C, Soria JC (2011) Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 47:2512\u20132516. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.012","journal-title":"Eur J Cancer"},{"key":"5507_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Ferte","year":"2014","unstructured":"Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C et al (2014) Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res\u202f: An Off J Am Assoc Cancer Res 20:246\u2013252. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2098","journal-title":"Clin Cancer Res : An Off J Am Assoc Cancer Res"},{"key":"5507_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.03.007","author":"M Winkelmann","year":"2023","unstructured":"Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bucklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P et al (2023) Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.007","journal-title":"Cytotherapy"},{"key":"5507_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"5507_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"5507_CR24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280189","author":"DMC Dos Santos","year":"2022","unstructured":"Dos Santos DMC, Rejeski K, Winkelmann M, Liu L, Trinkner P, Gunther S, Bucklein VL, Blumenberg V, Schmidt C, Kunz WG et al (2022) Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2021.280189","journal-title":"Haematologica"},{"key":"5507_CR25","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, Oberic L, Bodet-Milin C, Bories P, Olivier P et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 4:5607\u20135615. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001","journal-title":"Blood Adv"},{"key":"5507_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z et al (2019) Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant 25:1092\u20131098. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.008","journal-title":"Biol Blood Marrow Transplant"},{"key":"5507_CR27","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML et al (2020) High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4:3268\u20133276. https:\/\/doi.org\/10.1182\/bloodadvances.2020001900","journal-title":"Blood Adv"},{"key":"5507_CR28","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","volume":"100","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Simo M, Villacampa G, Catala E, Carpio C, Diaz-Lagares C, Vidal-Jordana A, Bobillo S, Marin-Niebla A, Perez A et al (2021) Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Ann Hematol 100:2303\u20132310. https:\/\/doi.org\/10.1007\/s00277-021-04560-6","journal-title":"Ann Hematol"},{"key":"5507_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","volume":"9","author":"A Titov","year":"2018","unstructured":"Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A et al (2018) The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis 9:897. https:\/\/doi.org\/10.1038\/s41419-018-0918-x","journal-title":"Cell Death Dis"},{"key":"5507_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","volume":"15","author":"S Champiat","year":"2018","unstructured":"Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferte C (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748\u2013762. https:\/\/doi.org\/10.1038\/s41571-018-0111-2","journal-title":"Nat Rev Clin Oncol"},{"key":"5507_CR31","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res\u202f: An Off J Am Assoc Cancer Res 23:1920\u20131928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1741","journal-title":"Clin Cancer Res : An Off J Am Assoc Cancer Res"},{"key":"5507_CR32","doi-asserted-by":"publisher","unstructured":"Wagner NB, Lenders MM, Kuhl K, Reinhardt L, Andre F, Dudda M, Ring N, Ebel C, Stager R, Zellweger C et al (2021) Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 9(5):e002350.\nhttps:\/\/doi.org\/10.1136\/jitc-2021-002350","DOI":"10.1136\/jitc-2021-002350"},{"key":"5507_CR33","doi-asserted-by":"publisher","unstructured":"Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C et al (2022) The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer 10(5):e004475. \nhttps:\/\/doi.org\/10.1136\/jitc-2021-004475","DOI":"10.1136\/jitc-2021-004475"},{"key":"5507_CR34","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frolich L, Ackermann J, Bucklein V et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138:2499\u20132513. https:\/\/doi.org\/10.1182\/blood.2020010543","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05507-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05507-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05507-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:04:19Z","timestamp":1704218659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05507-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5507"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05507-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All medical records and imaging studies were reviewed with the approval of the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 19\u2013817).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"V.B.: BMS\/Celgene: research funding; Kite\/Gilead: consultancy, honoraria, research funding; Janssen: research funding, honoraria; Novartis: research funding, honoraria; Roche: consultancy, research funding; Takeda: research funding. K.R.: Kite\/Gilead: research funding; Kite\/Gilead: travel support; Novartis: honoraria. V.L.B.: Amgen: honoraria; Celgene\/BMS: research funding; Kite\/Gilead: research funding, honoraria; Novartis: honoraria; Pfizer: honoraria. C.S.: Kite\/Gilead: travel support. M.v.B.: Astellas: consultancy, research funding, and honoraria; BMS: consultancy, research funding, and honoraria; Kite\/Gilead: consultancy, research funding, and honoraria; Miltenyi: consultancy, research funding, and honoraria; Mologen: consultancy, research funding, and honoraria; MSD Sharp & Dohme: consultancy, research funding, and honoraria; Novartis: consultancy, research funding, and honoraria; Roche: consultancy, research funding, and honoraria. M.S.: Amgen: research funding, speakers bureau; Astra Zeneca: speakers bureau; Aven Cell: consultancy; BMS\/Celgene: research funding, speakers bureau; CDR-Life: consultancy; Gilead: research funding, speakers bureau; GSK: speakers bureau; Ichnos Sciences: consultancy; Incyte Biosciences: consultancy; Janssen: research funding, consultancy, speakers bureau; Miltenyi Biotec: research funding, consultancy; Morphosys: research funding; Molecular Partners: consultancy; Novartis: research funding, consultancy, speakers bureau; Pfizer: consultancy, speakers bureau; Roche: research funding, speakers bureau; Seattle Genetics: research funding; Takeda: research funding, consultancy, speakers bureau. W.G.K.: Bristol Myers Squibb: advisor; mint Medical: advisor; Need, Inc: advisor; Boehringer Ingelheim, advisor. The remaining authors declare no competing financial interests. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}